FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386705352> ?p ?o ?g. }

• W4386705352 abstract "Importance Patients with refractory hypercholesterolemia who do not achieve their guideline-defined low-density lipoprotein cholesterol (LDL-C) thresholds despite treatment with maximally tolerated combinations of lipid-lowering therapies (LLTs) have an increased risk of atherosclerotic cardiovascular disease (ASCVD). Objective To evaluate longer-term efficacy and safety of evinacumab in patients with refractory hypercholesterolemia. Design, Setting, and Participants This randomized clinical trial included a 2-week screening period followed by a 16-week double-blind treatment period (DBTP) for subcutaneous regimens (evinacumab, 450 mg, once weekly [QW]; evinacumab, 300 mg, QW; evinacumab, 300 mg, every 2 weeks; or placebo QW) or a 24-week DBTP for intravenous regimens (evinacumab, 15 mg/kg, every 4 weeks [Q4W]; evinacumab, 5 mg/kg, Q4W; or placebo Q4W); a 48-week open-label treatment period (OLTP) for intravenous treatment only; and a 24-week follow-up period. Patients from 85 sites across 20 countries were recruited for the study; patients with primary hypercholesterolemia (defined as heterozygous familial hypercholesterolemia or established clinical ASCVD without familial hypercholesterolemia) who entered the 48-week OLTP were included. In addition, the patients’ hypercholesterolemia was refractory to maximally tolerated LLTs. Interventions All patients entering the OLTP received evinacumab, 15 mg/kg, intravenously Q4W. Main Outcomes and Measures Efficacy outcomes included change in LDL-C level and other lipid/lipoprotein parameters from baseline to week 72 (end of the OLTP). Safety outcomes included assessment of treatment-emergent adverse events (TEAEs). Results A total of 96 patients (mean [SD] age, 54.4 [11.3] years; 52 female [54.2%]) entered the OLTP, of whom 88 (91.7%) completed the OLTP. Mean (SD) baseline LDL-C level was 145.9 (55.2) mg/dL. At week 72, evinacumab, 15 mg/kg, reduced mean (SD) LDL-C level from baseline by 45.5% (28.7%) in the overall cohort. Evinacumab, 15 mg/kg, reduced mean (SD) apolipoprotein B (38.0% [22.1%]), non–high density lipoprotein cholesterol (48.4% [23.2%]), total cholesterol (42.6% [17.5%]), and median (IQR) fasting triglyceride (57.2% [65.4%-44.4%]) levels at week 72 from baseline in the overall cohort. TEAEs occurred in 78 of 96 patients (81.3%). Serious TEAEs occurred in 9 of 96 patients (9.4%); all were considered unrelated to study treatment. Conclusions and Relevance In patients with refractory hypercholesterolemia, evinacumab provided sustained reductions in LDL-C level and was generally well tolerated. Trial Registration ClinicalTrials.gov Identifier: NCT03175367" @default.
• W4386705352 created "2023-09-14" @default.
• W4386705352 creator A5006184249 @default.
• W4386705352 creator A5010266741 @default.
• W4386705352 creator A5032598384 @default.
• W4386705352 creator A5035375815 @default.
• W4386705352 creator A5042842097 @default.
• W4386705352 creator A5059427880 @default.
• W4386705352 creator A5060465607 @default.
• W4386705352 creator A5063992339 @default.
• W4386705352 creator A5081557648 @default.
• W4386705352 creator A5090781778 @default.
• W4386705352 date "2023-09-13" @default.
• W4386705352 modified "2023-10-01" @default.
• W4386705352 title "Longer-Term Efficacy and Safety of Evinacumab in Patients With Refractory Hypercholesterolemia" @default.
• W4386705352 cites W1844854928 @default.
• W4386705352 cites W2165624352 @default.
• W4386705352 cites W2609543937 @default.
• W4386705352 cites W2900034165 @default.
• W4386705352 cites W2995479243 @default.
• W4386705352 cites W3006057482 @default.
• W4386705352 cites W3046772142 @default.
• W4386705352 cites W3098138308 @default.
• W4386705352 cites W3113178943 @default.
• W4386705352 cites W3125520517 @default.
• W4386705352 cites W3137520281 @default.
• W4386705352 cites W4293253252 @default.
• W4386705352 doi "https://doi.org/10.1001/jamacardio.2023.2921" @default.
• W4386705352 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37703006" @default.
• W4386705352 hasPublicationYear "2023" @default.
• W4386705352 type Work @default.
• W4386705352 citedByCount "0" @default.
• W4386705352 crossrefType "journal-article" @default.
• W4386705352 hasAuthorship W4386705352A5006184249 @default.
• W4386705352 hasAuthorship W4386705352A5010266741 @default.
• W4386705352 hasAuthorship W4386705352A5032598384 @default.
• W4386705352 hasAuthorship W4386705352A5035375815 @default.
• W4386705352 hasAuthorship W4386705352A5042842097 @default.
• W4386705352 hasAuthorship W4386705352A5059427880 @default.
• W4386705352 hasAuthorship W4386705352A5060465607 @default.
• W4386705352 hasAuthorship W4386705352A5063992339 @default.
• W4386705352 hasAuthorship W4386705352A5081557648 @default.
• W4386705352 hasAuthorship W4386705352A5090781778 @default.
• W4386705352 hasBestOaLocation W43867053521 @default.
• W4386705352 hasConcept C121332964 @default.
• W4386705352 hasConcept C126322002 @default.
• W4386705352 hasConcept C142424586 @default.
• W4386705352 hasConcept C142724271 @default.
• W4386705352 hasConcept C197934379 @default.
• W4386705352 hasConcept C204787440 @default.
• W4386705352 hasConcept C27081682 @default.
• W4386705352 hasConcept C2778163477 @default.
• W4386705352 hasConcept C2779120738 @default.
• W4386705352 hasConcept C535046627 @default.
• W4386705352 hasConcept C71924100 @default.
• W4386705352 hasConcept C87355193 @default.
• W4386705352 hasConceptScore W4386705352C121332964 @default.
• W4386705352 hasConceptScore W4386705352C126322002 @default.
• W4386705352 hasConceptScore W4386705352C142424586 @default.
• W4386705352 hasConceptScore W4386705352C142724271 @default.
• W4386705352 hasConceptScore W4386705352C197934379 @default.
• W4386705352 hasConceptScore W4386705352C204787440 @default.
• W4386705352 hasConceptScore W4386705352C27081682 @default.
• W4386705352 hasConceptScore W4386705352C2778163477 @default.
• W4386705352 hasConceptScore W4386705352C2779120738 @default.
• W4386705352 hasConceptScore W4386705352C535046627 @default.
• W4386705352 hasConceptScore W4386705352C71924100 @default.
• W4386705352 hasConceptScore W4386705352C87355193 @default.
• W4386705352 hasLocation W43867053521 @default.
• W4386705352 hasLocation W43867053522 @default.
• W4386705352 hasOpenAccess W4386705352 @default.
• W4386705352 hasPrimaryLocation W43867053521 @default.
• W4386705352 hasRelatedWork W1977915442 @default.
• W4386705352 hasRelatedWork W2064879719 @default.
• W4386705352 hasRelatedWork W2085830368 @default.
• W4386705352 hasRelatedWork W2351796763 @default.
• W4386705352 hasRelatedWork W2351985199 @default.
• W4386705352 hasRelatedWork W2403502999 @default.
• W4386705352 hasRelatedWork W2567738959 @default.
• W4386705352 hasRelatedWork W4233016836 @default.
• W4386705352 hasRelatedWork W4297834875 @default.
• W4386705352 hasRelatedWork W4366141624 @default.
• W4386705352 isParatext "false" @default.
• W4386705352 isRetracted "false" @default.
• W4386705352 workType "article" @default.